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Résumé en
anglais
BACKGROUND & AIMS: Albumin infusion improves renal function and survival in
cirrhotic patients with spontaneous bacterial peritonitis (SBP) but its efficacy in
other types of infections remains unknown. We investigated this issue through a
multicenter randomized controlled trial.
METHODS: A total of 193 cirrhotic patients with a Child-Pugh score greater than 8
and sepsis unrelated to SBP were randomly assigned to receive antibiotics plus
albumin (1.5 g/kg on day 1 and 1g/kg on day 3; albumin group [ALB]: n=96) or
antibiotics alone (control group [CG]: n=97). The primary endpoint was the 3-month
renal failure rate (increase in creatinine ⩾50% to reach a final value ⩾133 μmol/L).
The secondary endpoint was 3-month survival rate.
RESULTS: Forty-seven (24.6%) patients died (ALB: n=27 vs. CG: n=20; 3-month
survival: 70.2% vs. 78.3%; p=0.16). Albumin infusion delayed the occurrence of
renal failure (mean time to onset, ALB: 29.0 ± 21.8 vs. 11.7 ± 9.1 days, p=0.018)
but the 3-month renal failure rate was similar (ALB: 14.3% vs. CG: 13.5%; p=0.88).
By multivariate analysis, MELD score (p<0.0001), pneumonia (p=0.0041),
hyponatremia (p=0.031) and occurrence of renal failure (p<0.0001) were predictors
of death. Of note, pulmonary edema developed in 8/96 (8.3%) patients in the
albumin group of whom two died, one on the day and the other on day 33 following
albumin infusion.
CONCLUSIONS: In cirrhotic patients with infections other than SBP, albumin
infusion delayed onset of renal failure but did not improve renal function or survival
at 3 months. Infusion of large amounts of albumin should be cautiously administered
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